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ABSTRACT 
Infection with hepatitis B virus (HBV) is a serious public health problem worldwide and leads to a wide 
spectrum of clinical presentations, ranging from asymptomatic carrier state to acute self-limiting infection or 
fulminant hepatic failure, chronic hepatitis with progression to cirrhosis, and hepatocellular carcinoma (HCC). 
Transmission of HBV from carrier mothers to their babies can occur during the perinatal period, and appears to 
be the most important factor in determining the prevalence of infection in high endemic areas. Three hundred 
(300) sera samples were screened among pregnant women attending a rural ante-natal clinic, using standard 
ELISA and the 5-panel test methods to estimate the prevalence, Markers and identify risk factors associated with 
the infection. Structured questionnaire was administered to subjects to obtain risk factors associated with the 
Hepatitis B Virus. Result showed a prevalence of 38 (12.6%) among the pregnant women screned.Based on Age, 
subjects aged 20-24 recorded the highest prevalence of 14(4.7%) years, closely followed by those aged 15-19 
with a prevalence of 10(3.3%) This Prevalence on age of subjects in this category was found to be statistically 
insignificant P>0.005. Subjects at the second trimester of pregnancy recorded a higher prevalence of 
34(11.3).P>0.005Seroloical markers showed; 28 (9.3%), 35 (11.6%), 5 (1.7%), 33(11.0%) and 20(6.7) for 
HBsAg, Anti HBs, HBeAg, Anti HBe and Anti HBc respectively (P< 0.005)}. The findings showed a high 
prevalence of HBV infection among pregnant women. Screening of women in this category therefore would help 
in the early detection of HBsAg and possible prevention of neonatal transmission; hence the need for routine 
antenatal screening of all pregnant women. 
Keywords: Screening, HBsAg, Hepatitis B markers, Pregnancy. 
    
1. INTRODUCTION 
Hepatitis is a general term meaning inflammation of the liver and can be caused by a variety of different viruses 
such as hepatitis A, B, C, D and E (Zuckerman, 2000). Hepatitis B is one of the world’s most common and 
serious infectious diseases. It is estimated that more than one third of the world’s population has been infected 
with the hepatitis B virus WHO,2008. 
 Globally, about one third of the population has been infected with HBV; six percent (6%) are chronic 
carriers and over 600,000 people die each year from acute disease or chronic sequelae secondary to HBV 
infection (Wright, 2006).  
 On the basis of the HBV carrier rate, the world can be divided in to high, medium and low endemic 
regions. The major concern is about high endemic countries, especially in Asia and Africa, where the most 
common routes of infection remain vertical transmission from mother to child and horizontal transmission 
between children (WHO, 2008).Most countries in Africa have a high HBV endemicity, with the exception of 
Morocco and Tunisia, which have intermediate endemicity (Su et al., 2010). A prevalence rate of 10% of HBV 
was found among pregnant women in Hong Kong (El et al., 2012) and 17.3% in Burkina Faso (WHO, 2004) and 
12% in Taiwan (Jacobsen et al., 2010). 
 The prevalence of HBV surface antigen (HBsAg) has been reported to vary substantially among 
African countries from less than 5% to up to 15% (Sutcliffe et al., 2002;Msuya et al.,2006; Pirillo et al., 2007). 
Sub-Saharan Africa is a region where the prevalence of anti-HBV antibodies and HBsAg is very high 
(Pawlotsky et al., 1995; Kurbanov et al., 2005; Makuwa et al., 2006; Bekondi et al,2007).Infection caused by 
hepatitis B virus (HBV) is a serious public health problem causing about two billion infections worldwide (El 
Khourya and Wallaceb,2012).Nigeria is classified among the group of countries endemic for HBV infection. A 
prevalence rate of 4.3 % was reported from Port Harcourt (Jacobsen et al., 2010), 5.7% from Ilorin, (Ott et al., 
2012), 11.6% from Maiduguri (Kershenobich et al., 2011) and 8.3% from Zaria (Kershenobich et al., 2011). A 
seroprevalence of 23.3% was reported among patients attending antenatal clinic at the Aminu Kano Teaching 
Hospital (AKTH) (Alvarado-Mora et al., 2011). 
 Individuals with chronic infection are at risk for the development of complications of chronic hepatitis 
B such as cirrhosis, hepatic decompensation, and hepatocellular carcinoma (Lavanchy, 2004 and Goldstein, 
2005). Chronic hepatitis B accounts for more than 600,000 deaths from decompensated cirrhosis or 
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hepatocellular carcinoma each year and is the 10th leading cause of death worldwide. (Lavanchy, 2004 and 
Goldstein, 2005). 
 Transmission is commonly through blood transfusion, blood products, use of contaminated needles, 
vertical transmission (mother to child through infected birth canal), and sexual contact (WHO, 2009). Neonates 
born of chronically infected mothers have a 70-90% risk of the infection progressing to a chronic phase (El 
Khourya and Wallaceb, 2012).  
 Vaccination is the most effective measure to reduce the global incidence of hepatitis B. Compared to 
other healthcare interventions, vaccination is an economically advantageous option, both in terms of cost-
effectiveness and benefit-cost ratios. In 1991, the World Health Organization (WHO) recommended that all 
countries introduce a policy of universal hepatitis B vaccination to prevent and control HBV infection and its 
long term sequelae on a global scale.  
 
2. MATERIALS AND METHODS 
Study area and population  
The research was carried out at Jos North and South LGA, Plateau State-Nigeria. Pregnant women at various 
trimesters attending antenatal clinic of the communities were recruited for this study. 
Ethical Clearance/Subject’s Consent 
Ethical clearance was sought and obtained from the ethical committee of the PSSH, while informed consent was 
obtained from each Volunteer included in the study.  
Questionnaire 
A well-structured questionnaire was issued to the subjects to obtain demographic and other relevant data. 
Sample collection 
3 mls of venous blood was collected, duly labeled and allowed to clot and sera carefully separated into cryovials 
and stored at -200C prior use. 
HBsAg TESTING: Assay of collected commenced by carrying out an On-the-spot testing for HBsAg  using the 
HBsAg test strip (Acon Laboratory incorporated USA), according to the manufacturer’s instructions. 
Confirmatory tests were then performed with Monolisa HBsAg ULTRA assay (HBsAg ELISA test reagent) 
(Biorad Laboratories,USA) which is a one-step enzyme Immunoassay according to the manufacturer’s 
instructions.  HBV-5 panel test for the qualitative assessment of the markers of hepatitis B virus infection in 
human serum, plasma and whole blood. The HBV Panel Test is an Immunochromatographic assay method to 
quickly detect five major markers of HBV infections, HBsAg, Anti-HBs (HBsAb), Anti-HBc (HBcAb), HBeAg 
and Anti-HBe (HBeAb) in human blood specimens. 
 
3. RESULTS AND DISCUSSION 
Prevalence of HBV among the pregnant women screened showed 38 (12.6%) Seropositivity. Based on Age, 
subjects aged 20-24 recorded the highest prevalence of 14(4.7%) years, closely followed by those aged 15-19 
with a prevalence of 10(3.3%) This Prevalence on age of subjects in this category was found to be statistically 
insignificant P>0.005.Table 1. Subjects at the second trimester of pregnancy recorded a higher prevalence of 
34(11.3).P>0.005,Table 2.Risk factors among Pregnant women screened showed that 14(4.6%) of subjects that 
tested positive had history of sharing sharp objects such as razor blades, nail cutters and scissors. This is 
followed by those who had history of blood transfusion 3(1.0%) P>0.005, Table 3.Educational status of subjects 
screened showed that subjects with Secondary level of Education recorded 21(7.0) Prevalence, Table 4. 
Prevalence of Markers among positive subjects screened, showed that the highest rate of positivity for HBsAg 
was 9.3%, the HBeAg recorded 1.7%.Anti-HBs which indicates antibody to the HBsAg showed 11.6% while 
Anti-HBe positivity recorded 11.0%, Anti-HBc Positivity showed 6.7%,) Table 5.Changes in Liver Enzymes 
among subjects that tested positive for the HBV showed a record of 26.3% Abnormality in ALT.  
Table 1: Distributions of Pregnant women screened based on Age. 
 Total Number 
Exam. (%) 
No.  
Pos.   (%) 
No. Negative  
(%) 
P-value OR 95% C.I 
Age (years)     1.33 0.33-5.36 
   15-19  60  (20.0) 10(3.3) 50   (16.7)  0.69 0.18-2.60 
   20-24 150 (50.0) 14   (4.7) 136 (45.3)  1.41 0.33-
6.10 
   25-29 40  (13.3) 7   (2.3) 33   (11.0)  1.16 0.23-5.81 
   30-34 
   35-39                              
   40-44                                                                         
27  (9.0) 
10  (3.3) 
8   (2.7)
4   (1.3) 
2   (0.7) 
1 (0.3)
23    (1.7) 
8      (2.7) 
7      (2.3) 
0.070 1  
   45-49 5   (1.7) 0   (0) 5      (1.7)    
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Table 2: Distributions of Pregnant women screened based on Trimester. 
 Total Number 
Exam. (%) 
No.  
Pos.   (%) 
No. Negative  
(%) 
P-value OR 95% C.I 
       
Trimester       
   First 8    (2.7) 0     (0.0) 8       (2.7)  - - 
   Second 243(81.0) 34  (11.3) 209   (69.7)  1.83 0.62-5.42 
   Third 49  (16.3) 4    (1.3) 45     (15.0) 0.150 1  
       
Table 3: Distributions of Pregnant women screened based clinical Risk Factors.  
 Total Number 
Exam. (%) 
No.  
Pos.   (%) 
No. Negative  
(%) 
P-value OR 95% C.I 
       
Exposure to risky behaviors      
 (Sharing of  sharp objects)      
      Yes 80   (26.6) 14  (4.6) 66     (22.0)  1  
      No 220 (73.3) 24  (8.0) 196   (65.3) 0.114 1.73 0.85-3.54 
History of Blood Transfusion      
      Yes 16   (5.3) 3   (1.0) 13      (4.3)  1  
      No 284(94.7) 35 (11.6) 249   (83.0) 0.223 1.64 0.45-6.05 
History of Vaccination      
 
      Yes 
67    (22.3) 1   (0.3) 66      (22.0)  1  
      No 233  (77.7) 37 (12.3) 196    (8.03) 0.119 0.08 0.01-0.60 
      
      
 
Table 4: Distributions of Pregnant women screened based on demographic Factors and Educational 
Status. 
 Total Number 
Exam. (%) 
No.  
Pos.   (%) 
No. Negative  
(%) 
P-value OR 95% C.I 
   Family 
status: 
      
    Monogamy 239  (79.7) 27 (9.0) 212     (70.1)  1  
      Polygamy 61    (20.3) 11(3.6) 50      (16.7)  0.151 0.58 0.27-2.25 
   Educational 
status: 
      
      Primary 50   (16.7) 3  (1.0) 47      (15.7)  0.69 0.17-2.71 
      Secondary 136 (45.3) 21( 7.0) 115    (38.3)  1.96 0.83-4.64 
      Tertiary 20   (6.7) 6  (2.0) 14      (4.7)  4.61 1.39-15.29 
      Informal 94   (31.3) 8  (2.6) 86      (28.6) 0.045 1  
 
KEY: OR = Odd ratio.CI = Confidence Interval 
 
Table 5 - Prevalence of HBV markers among Positive subjects screened 
  HBsAg HBeAg Anti- HBs Anti- HBe    Anti- HBc  P-Value 
  Results No. (%) No. (%) No. (%) No. (%)       No. (%)    
                        
Positive 
Negative 
 
Total 
28 (9.3) 
272(90.) 
 
300(100) 
5 (1.7) 
295(98.0 
 
300(100) 
35 (11.6) 
265(88.0 
 
300(100) 
33(11.0) 
267(89.0) 
 
300(100.0) 
20(6.7) 
280(93.3) 
 
300(100.0) 
P<0.0001 
 
DISCUSSION 
Neonates who contract Hepatitis B Virus will have almost 90% risk of developing chronic HBsAg carriage and 
chronic liver disease. Infants may also spread the disease to siblings and to the community Sriprakash and Anil 
(1997). About 80-90% of chronic infections have been found amongst infected neonates born to HBsAg positive 
carrier mothers, followed by 30% of children uninfected before 6-months of age (Vranckx et al., 1999) 
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When a pregnant woman is infected with HBV, there is a chance she may infect her fetus; 10-20% of 
women seropositive for HBsAg transmit the virus to their neonates (Vranckx et al., 1999). In women who are 
seropositive for both HBsAg and HBeAg, mother-to-child transmission is approximately 90%. (Rumi, et al., 
1998; Luka, et al., 2008). 
In this study, 12.6% of pregnant women screened in our location of study were seropositive for the 
HBsAg. A similar work by Ndako et al, (2012) among pregnant women in Bayara Bauchi recorded a prevalence 
of 17.2%. The result obtained is significant if compared with a related study in Maiduguri which showed that 
prevalence increased from 11.6% in 1994 to 15.8% in 1999 (Onwuka and Baba,1999). The study by Ndams et al, 
2008 among pregnant women at Minna, reported 12.3% prevalence. 
Furthermore, the results obtained in this study are equally higher than those obtained by Pennap et al, 
(2011) who recorded a prevalent rate of 6.67% among pregnant women attending ante- natal clinic in Federal 
Medical Center Keffi, from Zaria, (8.3%) prevalence in a study carried out in Northwest Nigeria (Luka et al, 
2008 and Jatau et al, 2009) and from Port Harcourt, South Nigeria (2.89%) prevalence was reported by (Obi et al, 
2006) while Akani et al, 2005 reported a prevalent rate of 4.3% and  from Ilorin, North Central Nigeria (Agbede, 
et al., 2007) recorded a prevalence of 5.7% in a study conducted among  mothers and their pre-school children. 
In this study women aged 20-24 recorded 4.7% prevalence compared to other age groups, this is 
compared to the work of Ndako et al, (2011)  where women aged 20-29 recorded 6.1%   prevalence. This is 
however contrary to the report of Pennap et al,(2011) who recorded a high  prevalence of 12.5% among pregnant 
women aged 40-44.The resultant high prevalence among this age group in our study is attributed to the fact that 
these women fall within the sexually active age bracket.According to Zali et al,(1996),age is an important factor 
in epidemiological studies hence the age of acquiring infection was found to be a major determinant of the 
incidence of HBV. 
Most of the women studied were in the 2nd trimester of gestation, this group also had the highest 
HBsAg seropositivity of 11.3%, the result obtained in this study is similar to those of Ndako et al,(2011) where 
most of the women studied were also in their 2nd trimester of gestation, with a seropositivity of 12.8%, this is 
however lower than those of Ndams et al, 2008 who obtained a higher prevalence of 13.4% at the 2nd trimester 
of pregnancy. 
Women with a history of blood transfusions recorded a prevalence of 1.0%, while those with history of 
use of unsterilized/sharp instruments also recorded 4.6% prevalence which was statistically higher compared to 
other risk factors. This implies that the infections in this class of women possibly resulted from wounds obtained 
from exchange or re-use of sharp instruments. 
Transmission mechanisms of infection include vertical transmission from mother to child, which is 
associated with a greater probability of generating carriers and consequently of maintaining the infection in the 
population. Some authors point out that the proportion of carriers among children born to mothers with a history 
of HBsAg seropositivity can range between 70% and 90% (Sáenz-González et al,2001) Thus, inclusion of the 
vaccine against HBV in the universal vaccination program has been recommended among the strategies for 
controlling the infection (WHO,2008). These screening programs would allow the timely administration of a 
vaccine in newborns born to seropositive mothers (Sáenz-González et al,2001). 
Sociodemographic factors, most importantly the level of health education on prevention, may play a 
role in our location of study. Other reasons include low economic status, low educational level, lack of early 
seeking of health-care assistance, and absence of a better effective utilization of available health-care facilities. 
In endemic areas, where the rate is >5%, most individual are infected from a carrier mother to her baby 
through placenta and during delivery (vertical transmission) or in early childhood while horizontal transmission 
is also possible among children, families and close personal relations (Dufour et al., 2000). Without intervention, 
a mother who is positive for HBsAg has a 20% risk of passing the infection to her offspring at the time of birth. 
This risk is as high as 90% if the mother is also positive for HBeAg.  Hepatitis B virus has a high rate of vertical 
transmission causing congenital infections in babies born to infected mothers. The finding of this present study 
confirms the findings of earlier studies that HBV is endemic in Nigeria. It has also shown that ignorance remains 
a key factor in the spread of HBV in Nigeria, (Onwuliri et al, 2008). From this study the highest rate of positivity 
recorded with regards to seromarkers involved the HBsAg with 9.3%, according to (Lee, 2010). 
The presence of HBsAg for longer than 6 months after acute infection indicates chronic infection. The 
detection of HBsAg and absence of IgM anti-HBc in a single serum specimen also generally indicates chronic 
HBV infection. Shortly after the appearance of the HBsAg, the hepatitis B e antigen (HBeAg) generally becomes 
evident (Ganem and Prince, 2004).Although serum HBV DNA assays will show the presence of HBV DNA 
prior to the appearance of HBsAg or HBeAg, with HBV DNA levels,(Rehermann et al.,1996). 
The HBeAg recorded in this study showed 1.7%.Previous study (Yang et al, 2004) reported that the 
presence of HBeAg in serum indicate active viral replication. The continued presence of HBeAg generally 
reflects higher HBV DNA levels and greater infectiousness according the study, Some patients with chronic 
HBV infection may have resolution of their HBeAg along with appearance of anti-HBe, and this usually 
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correlates with low (or absent) HBV levels and relatively normal levels of hepatic aminotransferase levels 
(Lee,1997).Conversely, Anti-HBe recorded 11.0%. Anti-HBs which indicate antibody to the HBsAg showed 
11.6% While Anti-HBs recorded 18.7% positivity among subjects aged 15-19years, subjects aged 25-29 years 
recorded 8.4% positivity to the Anti-HBs. For those patients who resolve their infection, HBsAg disappears at 
about 3 to 6 months, often just prior to the detection of antibodies to hepatitis B surface antigen (anti-HBs).The 
presence of anti-HBs following acute infection generally indicates recovery and protective \immunity against re-
infection. In addition, patients with resolution of infection have disappearance of HBeAg and development of 
antibodies to hepatitis B e antigen (anti-HBe). Patients with resolved infection have persistence of anti-HBc for 
life, but about 4 to 6 months after the appearance of anti-HBc, the total anti-HBc predominantly consists of IgG. 
Some patients with self-limited infection, however, may still have low levels of HBV DNA in blood; whether the 
HBV DNA is part of intact virions remains unknown (Rehermann,1996).Earlier studies (Zhang et al, 2010) 
reported that the history of vaccination could be attributed to HBsAb positivity, which should increase the 
confidence of the population on immunization process. 
Changes in Liver enzymes in the study conducted by Tsai et al,(2008), showed that Liver function tests 
are used to determine if the liver has been damaged or its function impaired. Elevations of certain liver tests in 
relation to others aids in that determination. The aminotransferases (which include ALT and AST) are notably 
elevated in liver damage caused by liver cell disease (hepatocellular disease). Alanine aminotransferase (ALT), 
Pregnant women screened in this study recorded 26.3% Abnormality in ALT levels which have been correlated 
positively with liver inflammation, while patients with persistently normal ALT levels had significantly lower 
liver damage compared with patients with either intermittent of persistently elevated ALT Levels (Zhang et al, 
2011).Therefore measurement of aminotransferase levels by serial observations and analysis remain the most 
common and convenient way to identify liver inflammation in patients particularly with chronic HBV infection.  
 
4. CONCLUSION AND RECOMMENDATION 
The reported prevalence in this study is a cause for concern and warrants the initiation of routine antenatal 
screening for HBV infection within communities. Similarly, HBV positive pregnant women represent a major 
reservoir of the virus in any community and can be passed on to the children either vertically or even 
horizontally. This finding equally underscores the need for a comprehensive programme of action to reverse the 
present state of endemicity and to halt further spread of the virus. It is hereby strongly recommended that 
awareness campaign about the disease be intensified while public immunization of the populace is highly 
encouraged. 
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